Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti-diabetic agents
Boucher M, McAuley L, Brown A, Keely E, Skidmore B
Record ID 32003000841
English, French
Authors' objectives:
1. To evaluate the evidence that compares rosiglitazone or pioglitazone with other oral anti-diabetic agents (including insulin), either when used alone or when added to a non-thiazolidionedione agent in the treatment of type 2 diabetes.
2. To determine the impact of listing thiazolidinediones on the budget of provincial drug plans in Canada.
Authors' recommendations:
When used alone, both rosiglitazone and pioglitazone have effects similar to comparator drugs on glycosylated hemoglobin (HbA1c) and fasting plasma glucose (FPG), based on the findings from a small number of comparative trials.
- When added to another anti-diabetic agent, the effect on HbA1c and FPG is significantly greater than continuing therapy with the other anti-diabetic agent alone. This is consistent with the work of others that shows combining two anti-diabetic agents provides a greater effect than using one alone.
- Both drugs were generally well tolerated during the trials reviewed; only a few cases of heart failure and severe hypoglycemia (when added to another agent) were reported. No liver toxicity was observed. Long-term trials are required to evaluate their effect on the development of diabetic complications and long-term safety.
- Based on the budget impact analysis, it is estimated that by 2004, if rosiglitazone and pioglitazone receive formulary listing throughout Canada, the net expenditure for the publicly-funded drug programs would increase nationally between $11.8 and $88.5 million per year, depending upon their utilization and the number of patients treated.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Diabetes Mellitus
- Hypoglycemic Agents
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.